Pepdox
Studies
Peptides
Calculator
A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena. | Pepdox
Home
/
Search
/
PMID 37385276
A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena.
Lancet (London, England)
2023
PMID: 37385276
View on PubMed
DOI: 10.1016/S0140-6736(23)01182-0
Retatrutide
Tirzepatide
Authors
Bain, Stephen C; Min, Thinzar